Win for AstraZeneca, Bristol-Myers Upheld in Diabetes Drug MDL

AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Co., and McKesson Corp. won’t face revived claims in multidistrict litigation over diabetes drugs because they were properly dismissed for a lack of expert evidence linking the medication to heart failure, the Sixth Circuit said.

The drugs are Onglyza and Kombiglyze, both of which contain saxagliptin as an active ingredient. The plaintiffs alleged saxagliptin caused heart failure. The district court granted summary judgment to the defendants.

The US District Court for the Eastern District of Kentucky didn’t err when it excluded the plaintiffs’ causation expert, cardiologist Parag Goyal, and refused to give the ...